Abstract

Exelixis is reaping the benefits of a licensing and development deal with GlaxoSmithKline that gives the pharma partner an option on 3 of 12 specified products in development.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call